BG104122A - 2-[3-[4-(2-трет.бутил-6-трифлуорометилпиримидин-4-ил) пиперазин-1-ил]пропилмеркапто] пиримидин-4-олфумарат - Google Patents

2-[3-[4-(2-трет.бутил-6-трифлуорометилпиримидин-4-ил) пиперазин-1-ил]пропилмеркапто] пиримидин-4-олфумарат

Info

Publication number
BG104122A
BG104122A BG104122A BG10412200A BG104122A BG 104122 A BG104122 A BG 104122A BG 104122 A BG104122 A BG 104122A BG 10412200 A BG10412200 A BG 10412200A BG 104122 A BG104122 A BG 104122A
Authority
BG
Bulgaria
Prior art keywords
propylmercapto
trifluoromethylpyrimidin
tret
piperazin
pyrimidin
Prior art date
Application number
BG104122A
Other languages
English (en)
Inventor
Stefan Blank
Dorothea Starck
Hans-Joerg Treiber
Stefan Koser
Bernd Schaefer
Marco Thyes
Thomas Hoeger
Original Assignee
Abbott Gmbh & Co. Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Gmbh & Co. Kg filed Critical Abbott Gmbh & Co. Kg
Publication of BG104122A publication Critical patent/BG104122A/bg

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/56—One oxygen atom and one sulfur atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Изобретението се отнася до сол на фумаровата киселина с 2-{3-[4-(2-трет.-бутил-6-трифлуорометилпиримидин-4-ил)пиперазин-1-ил]пропилмеркапто}пиримидин-4-ол и до фармацевтично средство, което я съдържа. Солта може да се използва за лечение на заболявания, които са зависими от допамин-D3-лиганди. Тя емного стабилна при ниско рН и затова е особено подходяща за орално приложение.
BG104122A 1997-08-14 2000-02-03 2-[3-[4-(2-трет.бутил-6-трифлуорометилпиримидин-4-ил) пиперазин-1-ил]пропилмеркапто] пиримидин-4-олфумарат BG104122A (bg)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19735410A DE19735410A1 (de) 1997-08-14 1997-08-14 2-{3-[4-(2-t-Butyl-6-trifluormethylpyrimidin-4-yl)piperazin-1-yl]propylmercapto}pyrimidin-4-ol-fumarat
PCT/EP1998/005178 WO1999009015A1 (de) 1997-08-14 1998-08-14 2-{3-[4-(2-t-butyl-6- trifluormethylpyrimidin-4-yl) piperrazin-1-yl] propylmercapto} pyrimidin-4-ol-fumarat

Publications (1)

Publication Number Publication Date
BG104122A true BG104122A (bg) 2000-11-30

Family

ID=7839072

Family Applications (1)

Application Number Title Priority Date Filing Date
BG104122A BG104122A (bg) 1997-08-14 2000-02-03 2-[3-[4-(2-трет.бутил-6-трифлуорометилпиримидин-4-ил) пиперазин-1-ил]пропилмеркапто] пиримидин-4-олфумарат

Country Status (25)

Country Link
US (1) US20010020022A1 (bg)
EP (2) EP1003728B1 (bg)
JP (1) JP4444492B2 (bg)
KR (1) KR100571945B1 (bg)
CN (1) CN1267286A (bg)
AR (1) AR016605A1 (bg)
AT (1) ATE525362T1 (bg)
AU (1) AU749575B2 (bg)
BG (1) BG104122A (bg)
BR (1) BR9811177A (bg)
CA (1) CA2301297A1 (bg)
CO (1) CO4960663A1 (bg)
DE (1) DE19735410A1 (bg)
ES (1) ES2374156T3 (bg)
HU (1) HUP0003710A3 (bg)
ID (1) ID24639A (bg)
IL (1) IL134246A (bg)
NO (1) NO314935B1 (bg)
NZ (1) NZ502675A (bg)
PL (1) PL201927B1 (bg)
SK (1) SK1182000A3 (bg)
TR (1) TR200000406T2 (bg)
TW (1) TW467912B (bg)
WO (1) WO1999009015A1 (bg)
ZA (1) ZA987239B (bg)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2311012T3 (es) * 2000-03-27 2009-02-01 ABBOTT GMBH & CO. KG Ligandos del receptor d3 de la dopamina para el tratamiento de la adiccion.
DE10101307A1 (de) * 2001-01-12 2002-08-01 Fumapharm Ag Muri Fumarsäurederivate als NF-kappaB-Inhibitor
DE102004027358A1 (de) 2004-06-04 2005-12-29 Abbott Gmbh & Co. Kg Pyrimidinverbindungen und ihre Verwendung
CA2574827C (en) * 2004-08-09 2013-05-07 Abbott Gmbh & Co. Kg 4-piperazinyl-pyrimidine compounds suitable for treating disorders that respond to modulation of the dopamine d3 receptor
CN102887860B (zh) * 2012-09-29 2015-07-01 上海泰坦科技有限公司 4-氯-6-三氟甲基嘧啶类化合物的制备方法
DK2906221T3 (da) 2012-10-11 2019-07-22 Southern Res Inst Urinstof og amidderivater af aminoalkylpiperaziner og anvendelse deraf
US9376396B2 (en) 2012-10-22 2016-06-28 AbbVie Deutschland GmbH & Co. KG Acylaminocycloalkyl compounds suitable for treating disorders that respond to modulation of dopamine D3 receptor

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4425143A1 (de) * 1994-07-15 1996-01-18 Basf Ag Substituierte Pyrimidinverbindungen und deren Verwendung

Also Published As

Publication number Publication date
WO1999009015A1 (de) 1999-02-25
KR100571945B1 (ko) 2006-04-18
TW467912B (en) 2001-12-11
PL338603A1 (en) 2000-11-06
EP1003728A1 (de) 2000-05-31
HUP0003710A3 (en) 2002-01-28
AU749575B2 (en) 2002-06-27
NO20000665D0 (no) 2000-02-10
PL201927B1 (pl) 2009-05-29
BR9811177A (pt) 2000-07-25
JP4444492B2 (ja) 2010-03-31
EP2272833A1 (de) 2011-01-12
DE19735410A1 (de) 1999-02-18
CO4960663A1 (es) 2000-09-25
AR016605A1 (es) 2001-07-25
NZ502675A (en) 2001-06-29
ZA987239B (en) 2000-02-14
NO20000665L (no) 2000-02-10
TR200000406T2 (tr) 2000-05-22
CA2301297A1 (en) 1999-02-25
ATE525362T1 (de) 2011-10-15
CN1267286A (zh) 2000-09-20
IL134246A (en) 2002-11-10
US20010020022A1 (en) 2001-09-06
ES2374156T3 (es) 2012-02-14
SK1182000A3 (en) 2000-09-12
EP1003728B1 (de) 2011-09-21
HUP0003710A2 (hu) 2001-10-28
JP2001515070A (ja) 2001-09-18
KR20010022833A (ko) 2001-03-26
ID24639A (id) 2000-07-27
NO314935B1 (no) 2003-06-16
IL134246A0 (en) 2001-04-30
AU9342698A (en) 1999-03-08

Similar Documents

Publication Publication Date Title
SI0955295T1 (en) Therapeutically active levorotatory and dextrorotatory 1-((4-chlorophenyl)phenylmethyl) piperazines
NO995006L (no) Nye forbindelser
ZA200205265B (en) A novel crystalline form of N-[4-[2-[2-amino-4,7-dihydro-4-oxo-3H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]L-glutamic acid and process therefor.
IL118889A0 (en) N-(aroyl) glycine hydroxamic acid derivatives and related compounds
WO2000058293A3 (en) Glucokinase activators
MY172823A (en) Formulation of human antibodies for treating tnf-() associated disorders
MY114389A (en) Aqueous risperidone formulations
IL142011A0 (en) Stable concentrated insulin preparations for pulmonary delivery
CA2004747A1 (en) Substituted phenylpyrimidines useful in the treatment of cns disorders
HRP20010584B1 (en) N-[2-hydroxy-3-(1-piperidinyl)propoxy]pyridine-1-oxide-3-carboximidoyl chloride and its use in the treatment of insulin resistance
AU1562988A (en) DNA clone of human thrombomodulin
TW223061B (en) 9-(3-cyanophenyl)-3,4,6,7,9,10-hexahydro-1,8-(2h,5h)-acridinedione and pharmaceutical compositions containing same
AU2868689A (en) Use of 1,4-disubstituted-piperidinyl compounds in the manufacture of a medicament for the treatment of insomnia
WO2003031447A3 (de) Pyrimidinderivate mit pde-v hemmender wirkung
IT1222395B (it) Composizione farmaceutica per somministrazione intranasale comprendente l'ormone ghrh,un agonista colinergico e/o un sale biliare
IL162314A0 (en) Use of pyridine-2,4-dicarboxylic acid diamides andof pyrimidine-4,6-dicarboxylic acid diamides for selective collagenase inhibition
AU5781298A (en) Wettable or water-soluble granular agrochemical composition
AU3523295A (en) Quinoxaline derivatives useful in therapy
TR200000406T2 (tr) 2-{3-[4-(2-T-Butil-6-Triflormetilpirimidin-4-il) piperazin-1-il] propilmerkapto} pirimidin-4-ol-fümerat.
TR199801184T2 (xx) Analjezik tesirli yeni bile�ikler.
TW349864B (en) Use of N-(pyridinyl)-1H-indol-a-amines for the preparation of a medicament for the treatment of obsessive-compulsive disorders
AU3749195A (en) Bis-2-aminopyridines, preparation method therefor and use tereof for controlling parasitic infections
GR3023896T3 (en) 2,3,4,5-tetrahydro-1h-3-benzazepines and pharmaceutically acceptable acid addition salts thereof.
ATE44875T1 (de) 4-amino-2-(imidazolidin-2-on-l-yl)-pyrimidin-5carbons|ure-(n-(3-trifluormethyl-phenyl)-amide) zur antithrombotischen prophylaxe und behandlung sowie ihre verwendung zur herstellung von antithrombotisch wirksamen arzneimitteln.
EP0333676A3 (en) Use of 1-(2-ethoxy-2-(3'-pyridyl)ethyl)-4-(2'methoxy-phenyl)piperazine, for the preparation of pharmaceutical compositions useful for the treatment of lower urinary tract disfunctions and benign prostatic hypertrophy